Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Davita Healthcare Partners Inc (DVA)

Davita Healthcare Partners Inc (DVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Here's What to Expect From DaVita's Next Earnings Report

With a market cap of $7.3 billion, DaVita Inc. (DVA) is a leading provider of kidney dialysis services in the United States, operating a network of outpatient dialysis centers and clinical laboratories for patients with chronic kidney failure. It also offers hospital-based and home dialysis, integrated care programs, physician services, and comprehensive kidney care solutions.

The Denver, Colorado-based is set to announce its fiscal Q4 2025 results soon. Ahead of this event, analysts expect DVA to report an adjusted EPS of $3.24, a surge of 44.6% from $2.24 in the year-ago quarter. It has surpassed Wall Street's earnings estimates in three...

Fundamentals

See More
  • Market Capitalization, $K 7,333,221
  • Shares Outstanding, K 70,600
  • Annual Sales, $ 12,816 M
  • Annual Income, $ 936,340 K
  • EBIT $ 2,751 M
  • EBITDA $ 3,475 M
  • 60-Month Beta 0.99
  • Price/Sales 0.62
  • Price/Cash Flow 5.46
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 42.46% (+1.37%)
  • Historical Volatility 23.15%
  • IV Percentile 78%
  • IV Rank 56.63%
  • IV High 57.57% on 04/08/25
  • IV Low 22.74% on 02/18/25
  • Expected Move (DTE 1) 1.45 (1.36%)
  • Put/Call Vol Ratio 37.44
  • Today's Volume 9,878
  • Volume Avg (30-Day) 2,584
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 29,764
  • Open Int (30-Day) 23,781
  • Expected Range 104.65 to 107.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 3.24
  • Number of Estimates 2
  • High Estimate 3.29
  • Low Estimate 3.18
  • Prior Year 2.24
  • Growth Rate Est. (year over year) +44.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.00 +4.94%
on 01/14/26
120.61 -12.12%
on 12/16/25
-14.06 (-11.71%)
since 12/15/25
3-Month
101.00 +4.94%
on 01/14/26
130.82 -18.98%
on 10/29/25
-20.01 (-15.88%)
since 10/15/25
52-Week
101.00 +4.94%
on 01/14/26
179.60 -40.99%
on 01/31/25
-56.37 (-34.72%)
since 01/15/25

Most Recent Stories

More News
Here's What to Expect From DaVita's Next Earnings Report

DaVita is set to announce its fourth-quarter results soon, with analysts forecasting a double-digit increase in the company’s bottom-line figure.

XLV : 157.02 (-0.53%)
$SPX : 6,940.67 (+0.20%)
DVA : 105.82 (+1.88%)
Behind Berkshire’s Curtain: Is Greg Abel Preparing to Cut Davita Loose?

Davita hit its 23rd new 52-week low on Tuesday. Its stock is now within a few dollars of trading in double digits. That’s not a good thing, given that its share price was nearly $180 a year ago.

KO : 70.47 (-1.36%)
BRK.B : 492.28 (-0.18%)
AXP : 357.56 (-0.20%)
DVA : 105.82 (+1.88%)
UNH : 339.09 (+1.23%)
1 Value Stock on Our Buy List and 2 We Brush Off

1 Value Stock on Our Buy List and 2 We Brush Off

BWIN : 26.16 (-1.62%)
PAHC : 39.98 (+0.28%)
DVA : 105.82 (+1.88%)
3 Profitable Stocks That Concern Us

3 Profitable Stocks That Concern Us

HRL : 24.74 (+1.02%)
LMAT : 86.54 (+1.26%)
DVA : 105.82 (+1.88%)
Is DaVita Stock Underperforming the Dow?

As DaVita has underperformed relative to the Dow over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

HCA : 483.49 (+0.97%)
$DOWI : 49,442.44 (+0.60%)
DVA : 105.82 (+1.88%)
DaVita Names New Leaders to Accelerate Care Transformation

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach

DVA : 105.82 (+1.88%)
2 Small-Cap Stocks to Keep an Eye On and 1 That Underwhelm

2 Small-Cap Stocks to Keep an Eye On and 1 That Underwhelm

LMB : 86.53 (+3.13%)
NIC : 133.21 (+2.26%)
DVA : 105.82 (+1.88%)
3 of My Favorite Index Funds for 2026

If you want accessible, useful, and downright cheap funds to anchor your portfolio, these three index funds can do it better than most.

NVDA : 186.99 (+2.10%)
VHYAX : 44.64 (+0.29%)
JPM : 309.62 (+0.57%)
FUMBX : 10.36 (unch)
JNJ : 219.43 (+0.40%)
XOM : 129.04 (-0.89%)
VYM : 148.70 (+0.43%)
FXAIX : 240.65 (-0.53%)
DVA : 105.82 (+1.88%)
Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know

Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know

OPCH : 36.12 (+1.72%)
BLCO : 17.45 (+0.75%)
WST : 279.44 (+1.62%)
DVA : 105.82 (+1.88%)
RVTY : 115.34 (+3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals...

See More

Key Turning Points

3rd Resistance Point 109.34
2nd Resistance Point 107.10
1st Resistance Point 105.48
Last Price 105.82
1st Support Level 101.63
2nd Support Level 99.39
3rd Support Level 97.77

See More

52-Week High 179.60
Fibonacci 61.8% 149.57
Fibonacci 50% 140.30
Fibonacci 38.2% 131.03
Last Price 105.82
52-Week Low 101.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar